DBV Technologies SA revenue breakdown overview

DBV Technologies SA revenue for the last year amounted to 16.12 M USD, the most of which — 16.06 M USD — came from its highest performing source at the moment, Epicutaneous Immunotherapy Products, the year earlier bringing 4.93 M USD. The greatest contribution to the revenue figure was made by France — last year it brought DBV Technologies SA 16.06 M USD, and the year before that — 4.93 M USD.